CurrentUnitedHealthcarePolicy 2026T0560KK

Cell-Free Fetal DNA Testing (cfDNA/NIPT)

Defines UnitedHealthcare Commercial and Individual Exchange coverage position for cell-free fetal DNA testing (cfDNA/NIPT) including indications considered medically necessary (RhD/alloimmunization) and those considered unproven/not medically necessary (expanded genome-wide testing, twin zygosity, microdeletions, single-gene panels, fetal antigen status other than RhD). Also includes applicable CPT/PLA/HCPCS codes, definitions, and evidence review summaries.

Policy Summary

PayerUnitedHealthcare

PolicyCell-Free Fetal DNA Testing (cfDNA/NIPT)

Policy CodePolicy 2026T0560KK

Change TypeTemplate Update / Administrative

Effective DateJan 1, 2026

Next Review Date

Key ActionDocument that indicated invasive diagnostic testing was offered and declined when ordering cfDNA for alloimmunization/RhD indication.

POLICY UPDATE CHANGES

01/01/2026, Summary of Changes = Template Update; created shared policy version to support application to Oxford plan membership and archived previous versions.

1Primary covered indication (RhD/alloimmunization)

6Unproven/not medically necessary indications listed

7Referenced procedure/PLA/CPT codes

100%Fetal antigen assay concordance

PPV variability for CNVs

Coverage Summary

This policy (Policy Number 2026T0560KK) defines UnitedHealthcare Commercial and Individual Exchange coverage for cell-free fetal DNA testing (cfDNA/NIPT). The policy takes a mixed coverage stance: cfDNA testing to determine fetal genotype is considered medically necessary for management of alloimmunized or at-risk-for-alloimmunization pregnancies (e.g., RhD indications) when specified conditions are met, while expanded or genome-wide cfDNA testing and other listed indications are considered unproven/not medically necessary.

The policy is effective January 1, 2026 and replaces/updates prior versions as an administrative/template update to create a shared policy version (archived previous versions 2025T0560JJ and MATERNITY 025.35).

Surface quick facts

Effective dateJanuary 1, 2026

Policy number2026T0560KK

Primary covered indicationRhD/alloimmunization fetal genotype

Number of explicitly listed unproven indications6

Referenced procedure/PLA/CPT codes (count)7

Medical-Necessity Criteria

Medically Necessary Indication: cfDNA for fetal genotype in alloimmunized or at-risk-for-alloimmunization pregnancies

Covered when ALL of the following are met:

Indication: Individual undergoing testing is alloimmunized or at risk for alloimmunization due to maternal RhD status or presence of red cell antigen antibodies
Paternal genotype: Paternal genotyping shows heterozygosity for RhD or paternal RhD status is unknown
Offer of invasive testing: Indicated invasive diagnostic testing (e.g., amniocentesis, chorionic villus sampling [CVS]) for fetal genotyping has been offered and declined
Client must have been offered invasive diagnostic testing and declined

Provider Actions & Authorization Guidance

Documentation Required

Document offer and decline of invasive diagnostic testing

Document in the medical record that invasive diagnostic testing (e.g., chorionic villus sampling or amniocentesis) was offered and whether the patient declined. This documentation is required when cfDNA testing is being used in lieu of diagnostic testing and may be requested in medical record review.

Documentation Required

Paternal genotyping documentation

When applicable, document paternal genotyping results (including heterozygosity for RhD or specific antigen status) in the medical record. Paternal genotype information supports interpretation of cfDNA results and is a prerequisite for some covered indications (e.g., alloimmunized pregnancies).

Coding

Applicable molecular/CPT/PLA/HCPCS codes referencedmixed

0060U	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood.
0488U	Obstetrics (fetal antigen noninvasive prenatal test), cell-free DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies.
0489U	Obstetrics (single-gene noninvasive prenatal test), cell-free DNA sequence analysis of 1 or more targets (e.g., CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis reported as a fetal risk score.
0494U	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative.
0536U	Red blood cell antigen (fetal RhD), PCR analysis of exon 4 of RHD gene and housekeeping control gene GAPDH from whole blood in pregnant individuals at 10+ weeks gestation known to be RhD negative, reported as fetal RhD status.
81422	Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood.
81479	Unlisted molecular pathology procedure

Evidence Summary

Background: cfDNA (cell-free fetal DNA or cffDNA) testing is a noninvasive screening method that analyzes fetal-derived cfDNA in maternal plasma and can be offered as early as 10 weeks gestation. These assays can screen for common chromosomal aneuploidies and other genomic abnormalities but are screening tests, not diagnostic — only invasive procedures (chorionic villus sampling or amniocentesis) can definitively diagnose fetal genetic conditions.

Limitations and key evidence areas reviewed: the policy reviews diagnostic accuracy and clinical utility data for RhD genotyping (high sensitivity/specificity in multiple studies), evidence and guidance on genome-wide/expanded cfDNA for rare autosomal trisomies and copy number variants (CNVs) (limited data, variable PPVs, high heterogeneity), performance of cfDNA for detection of specific CNVs including 22q11.2 (mixed sensitivity and PPV across studies), and emerging data on single-gene NIPT/sgNIPT and fetal antigen testing beyond RhD (promising but limited; additional validation needed).

Study / Evidence	Key result
RhD NGS study (Gilstrop et al. 2025)	Sensitivity 100% (95% CI 98.9-100%), Specificity 99.3% (95% CI 97.6-99.8%), PPV 98.4%, NPV ~100% beginning at 9 weeks gestation (cohort n=655)
Meta-analysis (Yang et al. 2019)	False negative rate 0.34% (95% CI 0.15-0.76), False positive rate 3.86% (95% CI 2.54-5.82); accuracy varies by gestational age; generally accurate after first trimester
Rego et al. fetal antigen cfDNA (2025)	100% sensitivity, specificity, and accuracy across 465 antigen calls (K1, E, C, Fya, c, RhD) with neonatal genotype concordance; tested 10 0/7 to 37 0/7 weeks
Alford et al. fetal antigen NGS/QCT	Analytical sensitivity and specificity 100% in preclinical validation; clinical concordance 100% in small cohorts; precision 99.9%
Sequenom genome-wide cfDNA CNV study (Soster et al. 2023)	Sensitivity 93.8% and specificity 97.3% for CNVs ≥7 Mb when specific microdeletions assessed; PPV 63.8%; sensitivity fell to 63.8% when out-of-scope CNVs treated as false negatives
Xue et al. NIPT-plus (31,260 pregnancies)	High-risk CNVs detected 0.71%; overall PPV 38.42%; PPV 75% for DiGeorge, 80% for 22q11.22 microduplication; combined PPV 46.5% for CNVs >10 Mb and 28.57% for ≤10 Mb
Konya et al. 2024 genome-wide RATs meta-analysis	Pooled PPV 0.07 (confirmed) and 0.13 (extended); pooled false positive rate 0.0020; high heterogeneity (I2=95%)
Hammer et al. 22q11.2 WGS study (2024)	Of 76 screen-positives for 22q11.2, 22 diagnostic results available and all confirmed (PPV 100%, 95% CI 84.6-100%), but sensitivity/specificity not assessed
Dar et al. SNP-based cfDNA for 22q11.2	Sensitivity 75%, specificity 99.84%, PPV 23.7% (improved to PPV 52.6% with updated algorithm)
Wynn et al. carrier screening reflex to sgNIPT (42,067)	sgNIPT sensitivity 96%, specificity 95.2% for evaluated subset; overall reflex workflow sensitivity 92.4%, specificity 99.9%
Hoskovec et al. sgNIPS (9,151)	Informative results in 98.7%; NPV 99.4%, average PPV 48.3% in subgroup with outcomes
Cui et al. NIPT CNV in pregnancies with ultrasound findings	Sensitivity 83.33% and specificity 99.34% for CNV >1 Mb; PPV 90.91%, NPV 98.68% (selected population with anomalies)

Definitions & Thresholds

FAQs

Question	Answer
Is cfDNA/NIPT diagnostic for CNVs or single-gene disorders?	No — cfDNA/NIPT is a screening test; positive results require confirmatory diagnostic testing such as microarray via amniocentesis.
Should cfDNA screening be offered to all pregnant individuals?	ACMG and ACOG/SMFM recommend offering cfDNA screening for common trisomies to all pregnant individuals; recommendations for expanded screening (CNVs, RATs) are conditional or state insufficient evidence.

Revision History

01/01/2026revisionLatest

Template Update; archived previous policy version 2025T0560JJ and MATERNITY 025.35.

Policy Summary

PayerUnitedHealthcare

PolicyCell-Free Fetal DNA Testing (cfDNA/NIPT)

Policy CodePolicy 2026T0560KK

Change TypeTemplate Update / Administrative

Effective DateJan 1, 2026

Next Review Date

Key ActionDocument that indicated invasive diagnostic testing was offered and declined when ordering cfDNA for alloimmunization/RhD indication.

On This Page

Not Medically Necessary / Unproven Indications

cfDNA using maternal plasma is considered unproven and not medically necessary for indications beyond screening for trisomies 21, 18, 13, and sex chromosome aneuploidy. This includes but is not limited to:

Twin zygosity: Testing for the sole purpose of determining Twin Zygosity
CPT 0060U references twin zygosity
Genome-wide/exome-wide: Genome-wide or exome-wide screening (e.g., MaterniT Genome)
Expanded panels: Cell-Free Fetal DNA expanded panel testing (panels that include testing beyond trisomies 21, 18, 13, and sex chromosome aneuploidy)
CNVs: Screening for microdeletions/microduplications/copy number variations (CNVs)
Evidence insufficient to support routine use; see studies of variable PPV/sensitivity
Single-gene disorders: Screening for single gene disorders (e.g., Vistara, PreSeek)
CPT 0489U references single-gene noninvasive prenatal test
Non-RhD fetal antigen: Screening for fetal antigen status other than RhD
Evidence limited; fetal antigen testing other than RhD lacks sufficient peer-reviewed evidence

General recommendations and limitations

Guidance and consensus statements summarized from professional societies; not direct coverage decision tree but informs coverage stance:

NIPT accuracy for common aneuploidies: NIPT is the most accurate screening test for common autosomal aneuploidies (trisomies 21, 13 and 18) in unselected singleton populations and those at increased probability; offered in primary or contingent screening models (ISPD summary).
Positive NIPT requires confirmation: Positive NIPT results are screening results and should be confirmed with diagnostic testing if termination of pregnancy is being considered (ASHG/ESHG, ISPD).
Expanded NIPT not recommended: Expanded NIPT to report sex chromosomal abnormalities and microdeletions is not recommended by ASHG/ESHG; insufficient data for routine NIPT for rare autosomal trisomies (RATs), subchromosomal imbalances, and microdeletion/duplication syndromes (ISPD/ACMG/others).
Genome-wide CNV screening not recommended: Genome-wide cfDNA screening for large deletions/duplications (CNVs) has not been clinically validated and is not recommended by ACOG/SMFM.
Fetal fraction QC: Fetal fraction is an important quality-control metric; laboratories should validate limits of detection and thresholds for 'no call' results; providers should have clinical pathways for 'no call' (ISPD).
Repeat screening considerations: Repeat cfDNA screening may be considered for early gestational age or sample concerns but repeat sampling delays diagnostic testing and is not advised when sonographic anomalies are present or delay may compromise reproductive options (ACOG).
Early first trimester scan: At least one early first trimester scan for dating, multiple pregnancy diagnosis, and confirmation of fetal viability should be offered before performing NIPT (ISPD).
Ultrasound anomalies and NT: Fetuses with ultrasound abnormalities, including NT ≥ 3.5 mm, should be offered diagnostic testing and chromosomal microarray regardless of prior NIPT result (ISPD).NT ≥ 3.5 mm

Prior Authorization

Prior authorization risk for non-covered indications

Prior authorization may be required and there is a denial risk when cfDNA testing is requested for indications that are not covered (for example, genome‑wide screening, expanded panels beyond trisomy 21/18/13 and sex chromosome aneuploidy, routine microdeletion/CNV screening, or single‑gene disorders outside of specified use). Verify medical necessity against the policy and obtain authorization when indicated.

Documentation Required

Confirmatory diagnostic testing after screen-positive cfDNA for CNVs/microdeletions

Positive cfDNA results for suspected copy number variations (CNVs) or microdeletions are screening results only. Advise and document that confirmatory diagnostic testing via chromosomal microarray or diagnostic karyotype (from CVS or amniocentesis) is recommended before making irreversible clinical decisions.

Documentation Required

No-call (nonreportable) cfDNA results follow-up

For nonreportable or "no‑call" cfDNA results (e.g., due to low fetal fraction or failed quality metrics), document follow‑up steps in the record. Options include repeat cfDNA sampling, early ultrasound assessment, or referral for diagnostic testing depending on clinical context and gestational age.

Documentation Required

Recommend genetic counseling

Recommend and document referral for genetic counseling both before testing (pretest counseling) and after positive or inconclusive results. Genetic counseling should cover test limitations, possible outcomes, and implications for diagnostic follow‑up and reproductive decision‑making.

Documentation Required

Pretest counseling and informed consent

Provide pretest counseling and obtain informed consent, documenting that the patient understands the scope and limitations of cfDNA screening (screening vs diagnostic), potential false positives/negatives, and the need for diagnostic confirmation when indicated.

Documentation Required

Offer single prenatal screening approach

Offer a single prenatal screening strategy discussion when appropriate. Document whether cfDNA screening is chosen as the primary screening modality versus combined first‑trimester screening, and the rationale in the medical record.

Documentation Required

Consideration of cfDNA in twin/multifetal gestations

In multifetal gestations, consider the limitations of cfDNA (reduced sensitivity/specificity, earlier gestational limits, and twin‑specific assays). Document that cfDNA testing in twin or higher‑order multiple pregnancies was considered and why it was or was not used.

Documentation Required

Use of cfDNA fetal antigen genotyping in alloimmunized patients

When using cfDNA fetal antigen genotyping (e.g., RhD) in alloimmunized patients, document maternal antibody status, rationale for testing, and how results will be used to guide management (including whether invasive diagnostic testing was offered and declined).

Documentation Required

Confirmatory diagnostic testing for positive NIPT

Positive NIPT/cfDNA results should be confirmed with diagnostic testing (CVS or amniocentesis with appropriate cytogenetic or molecular analysis) prior to definitive clinical actions (e.g., invasive procedures, pregnancy management decisions). Document that confirmatory testing was recommended.

Documentation Required

Management of 'no call' results

For 'no call' results management, document steps taken: repeat cfDNA sample timing, early ultrasound to evaluate viability and gestational age, consideration of maternal factors (e.g., high BMI) that may affect fetal fraction, and discussion of diagnostic testing when clinically indicated.

Documentation Required

Early ultrasound before NIPT

Recommend an early ultrasound (dating and viability assessment) prior to or concurrent with NIPT when gestational age, multiple gestations, or fetal anatomy evaluation may influence test selection, interpretation, or the need for alternative testing.